Clinical Trials

Clinical trials are research studies that test whether new medical treatments, devices or strategies  are safe and effective.

People who volunteer for clinical trials play an active role in their own health care, often gain access to experimental treatments, and help others by improving and advancing medical care.

At Providence Cancer Center, our scientists and physicians work closely together to make clinical trials a regular part of cancer care. Patients may take part in studies initiated by our translational researchers at the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute, in addition to studies sponsored by the National Cancer Institute or pharmaceutical and biotechnology companies.

Our clinical trials team works directly with physicians to identify clinical trials appropriate for their patients’ specific stage of disease.

The goals of clinical research vary from trial to trial. Generally, they are designed to:

  • Improve prevention, early diagnosis and treatment of cancer
  • Discover whether a particular drug  or medical treatment is safe and effective
  • Advance the state of scientific and medical knowledge
  • Measure and improve the quality of life for patients and their families
Find cancer clinical trials available in Oregon in the list below. You may search by keyword or condition/disease, or browse using the page numbers and arrows. Find additional trials by using the search term “Oncology Multiple Tumor Sites". To learn more about a particular trial and qualification criteria, click the trial name and then the listed contact link, or talk with your physician.

For more information about clinical trials available through Providence Cancer Center, call 503-215-6014
« Previous 12345 Next »
Viewing Page 1 of 26 | Showing Results 1 - 5 of 127

A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer

The purpose of this study is to examine if Nivolumab alone or in combination with Ipilimumab will demonstrate a meaningful objective response rate...

Todd Crocenzi MD
  • Oncology and Hematology Care Eastside
  • PH&S

A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma

The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) of...

Todd Crocenzi MD
  • Oncology and Hematology Care Eastside
  • PH&S

A Phase I Multiple Ascending Dose Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1)Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with or without Chronic Viral Infection.

The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the...

Todd Crocenzi MD
  • Oncology and Hematology Care Eastside
  • PH&S
  • Providence Portland Medical Center

A Phase III Trial Evaluating both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

This randomized phase II-R/III trial studies gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy...

Matthew Solhjem MD
  • Clackamas Radiation Oncology Center
  • PH&S
  • Providence Portland Medical Center
  • Providence St. Vincent Medical Center
« Previous 12345 Next »
Viewing Page 1 of 26 | Showing Results 1 - 5 of 127